{
    "organizations": [],
    "uuid": "32b49809cb25749fbd50c86c6f4139965438f481",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ocular-therapeutix-reports-q4-loss/brief-ocular-therapeutix-reports-q4-loss-per-share-0-44-idUSASB0C9EY",
    "ord_in_thread": 0,
    "title": "BRIEF-Ocular Therapeutix Reports Q4 Loss Per Share $0.44",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Ocular Therapeutix Inc:\n* OCULAR THERAPEUTIX™ REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND BUSINESS UPDATE\n* “REAFFIRM GUIDANCE THAT WE ARE ON TRACK FOR A RESUBMISSION OF OUR DEXTENZA NDA IN FIRST HALF OF 2018”\n* QTRLY LOSS PER SHARE $0.44 * Q4 EARNINGS PER SHARE VIEW $-0.52 — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T20:46:00.000+02:00",
    "crawled": "2018-03-09T14:15:46.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ocular",
        "therapeutix",
        "inc",
        "ocular",
        "report",
        "fourth",
        "quarter",
        "year",
        "end",
        "financial",
        "result",
        "business",
        "update",
        "reaffirm",
        "guidance",
        "track",
        "resubmission",
        "dextenza",
        "nda",
        "first",
        "half",
        "qtrly",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}